![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Doxepin hydrochloride is a psychotropic agent with antidepressant and anxiolytic properties as it binds with high affinity antagonist of histamine H1 receptor and exerts its sleep maintenance effect.
Lead Product(s): Doxepin Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Sinequan-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
The probiotic portfolio includes Sporlac, which is the third-largest probiotics brand in India, and specialised products like Lobun used for delaying progression of chronic kidney disease and Oxalo, an alternate risk-free therapy to decalcify kidney stones.
Lead Product(s): Lacticacid Bacillus
Therapeutic Area: Gastroenterology Product Name: Sporlac
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Sanzyme
Deal Size: $84.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 26, 2022
Details:
The USFDA has approved company's abbreviated new drug application (ANDA) for Loratadine tablets USP 10 mg for treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy.
Lead Product(s): Loratadine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021